News & Analysis on Clinical Trial Services & Contract Research And Development
French firm Diatos has created a second generation irinotecan cancer therapy using its patented peptide-based drug delivery system, coming up with a drug that has greatly improved efficacy and safety profile compared to current irinotecan drugs such...
A US start-up firm is gearing up to launch an online database where researchers can access a variety of drug discovery service providers across the globe.
Two major bioscience industry trade associations have called for changes to be made to the European clinical trials directive in order to bring about "harmonisation, transparency and consistency" in this area across the member states.
Three big industry names have been busily bolstering their pharma logistics clout: Thermo Fisher Scientific, UPS and Kuehne+Nagel.
LabTechnologist.com brings you its periodic update of recent product releases, with additions from Activotec, Applied Biosystems / MDS Sciex, FEI, Invitrogen, Mettler Toledo and Torrey Pines.
Agilent and BioTrove are collaborating to deliver ultra high-throughput sample preparation and mass spectrometry (MS) systems to speed the analysis of in vitro assays used in drug development.
A new solid-state proton NMR (nuclear magnetic resonance) technique has been developed that can quickly determine polymorphism of active pharmaceuticals within tablet formulations.
As men grow older, the majority of them will suffer from the symptoms of an enlarged prostate. However, help could be on the horizon from BioXell's new drug that treats both the symptoms and, crucially, the cause of this debilitating problem.
A new report has outlined a series of recommendations for government policymakers to help mitigate the potential risks of the burgeoning synthetic genomics area.
Swiss pharmaceutical and logistics company Galenica is to acquire Canadian pharmaceutical company Aspreva Pharmaceuticals for $915m (€645.2m).
Pfizer revealed today that it is abandoning its once-touted blockbuster Exubera, ending months of speculation as to whether the fledging world-first inhalable insulin would sink or swim in the fierce waters of pharma.